Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...
PhD Defense of W.P.J. Cox (UMC Utrecht/Kinderen) ...
Exploring the combination with azacitidineStudy led by Medical College of Wisconsin MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) ...
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), a micro-cap pharmaceutical company with a market capitalization of $3.12 million, has amended its agreement with contract research organization ...
Meanwhile, Dr. Manuel López-Figueroa and Dr. Carlos Buesa will remain on the Board, subject to a positive vote by the Shareholders’ Meeting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback